Literature DB >> 23967555

Morular endometrial metaplasia: review of the literature and proposal of the management.

P Litta1, A Codroma, G D'Agostino, E Breda.   

Abstract

PURPOSE OF INVESTIGATION: Morular endometrial metaplasia is a rare condition that can be often misdiagnosed and overtreated, because it can be mistaken for a malignant disease. The aim of this review was to update the current opinion on the significance of this pathology and its risk for potential malignancies.
MATERIALS AND METHODS: The authors report their experience of two cases of morular metaplasia involving very young women managed conservatively with hysteroscopic resection of the affected areas.
RESULTS: Hysteroscopic resection of these lesions can be an adequate and fertility-sparing treatment of morular metaplasia in women of childbearing age.
CONCLUSIONS: Morular metaplasia has indeed a mutational origin but it is a benign and hormonally inert condition. The risk to develop cancer is closely associated with premalignant or malignant endometrioid glandular proliferations that are often associated with hysthological finding of morules rather than with morules themselves. Management of this condition requires trained pathologists and gynecologists and should be adapted to the age of the patient.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23967555

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  2 in total

1.  Estimated intermediate risk endometrial cancer: debate and new perspectives on therapy individualization and prognosis establishment starting from a peculiar case.

Authors:  Salvatore Gizzo; Alberta Fabris; Pietro Litta; Carlo Saccardi
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

2.  Clinical implications of morular metaplasia in fertility-preserving treatment for atypical endometrial hyperplasia and early endometrial carcinoma patients.

Authors:  Pengfei Wu; Qiaoying Lv; Jun Guan; Weiwei Shan; Xiaojun Chen; Qin Zhu; Xuezhen Luo
Journal:  Arch Gynecol Obstet       Date:  2022-03-04       Impact factor: 2.493

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.